John Cumbers’ Post

As technology rapidly advances, we recognize the importance of empowering humanity with AI and Web 3.0. At K.i. Datavision, we believe that the benefits of AI are immense, including the reduction of waste and pollution and the acceleration of cell, gene, and drug therapy development. With our proprietary Cognitive K.i. technology, we are delivering previously unimaginable analysis of global data to thousands of companies, NGOs, and individuals. However, we must remain vigilant against overly dominant AI operators to safeguard our democratic rights. Come to us to explore embracing disruptive technology; to drive competition and be a part of quantum change in the next decade. Participate with our help towards a brighter future. #Datascience £AI #Web3.0 #pollution monitoring #DisruptiveTechnology #QuantumChange #CognitiveKi #KiDatavision

It's not often that you can trace back to the exact moment when an idea forms in your mind. The attached video is to within an hour, of when I decided to work on the project that has since become the startup, Biostate AI, that I co-founded with David Zhang. So, it's fitting that I share it while introducing our initial set of service offerings. Specifically, yesterday we publicly released three products that we have been developing on for the last year at Biostate: 1. Total RNAseq: A method for comprehensive RNA sequencing that measures all RNA types (mRNA, lncRNA, miRNA, etc.) at a cost 80-90% lower than existing methods. 2. Omicsweb: A repository of novel, proprietary data including time-varying, multi-organ, and cross-species data, all generated using our Total RNAseq technology. 3. Omicsweb co-pilot: An LLM (#ClaudeSonnet) powered agent for analyzing RNA-seq and other omics data. For more details on these offerings as well as on how the puppy fits into all this, check out my longer blog post: https://lnkd.in/gUnRkc-y To explore our products further, visit our website: Biostate.ai Many thanks to Dario Amodei, Emily Leproust, Michael Schnall-Levin, Joris Poort, Haomiao Huang, PhD (Matter Venture Partners) ,Rouz Jazayeri (Catapult Ventures), Vision Plus Capital and Caltech Fred Farina, for your support of Biostate AI! If this work interests you, and you want to collaborate or talk about it, feel free to DM me. #genai #ai #drugdiscovery #biotechinnovation #multiomics #rnaseq #omics

The Intersection of AI and Biotechnology 🧬 Today, let’s delve into a fascinating field where AI meets Biotechnology—a collaboration that’s transforming healthcare and beyond. 🔍 What is AI in Biotechnology? AI is revolutionizing biotechnology by accelerating drug discovery, improving diagnostics, and personalizing treatments. Machine learning algorithms can analyze vast amounts of biological data, uncovering patterns and insights that were previously hidden. 💉 Why It Matters: This synergy is leading to breakthroughs like faster vaccine development, AI-driven genomics, and more effective cancer treatments. The combination of AI and biotech is not only pushing the boundaries of science but also saving lives.The future of healthcare is here, and it’s powered by AI. #AIinBiotech #HealthcareInnovation #Biotechnology #FutureOfMedicine #TechMuj

New Release on BioFocus. BaseFold, developed by Basecamp Research, is breaking new ground in drug discovery by leveraging AI to predict complex protein structures with unprecedented accuracy. While AI tools like AlphaFold2 paved the way, BaseFold propels the field further into the future by utilizing diverse biological data from global biodiversity—predicting structures of larger, more complex proteins and enhancing small molecule interaction predictions. This advancement has massive potential for tackling diseases like cancer, neurodegenerative disorders, and antimicrobial resistance. Read the article to learn how BaseFold is unlocking new horizons in personalized medicine and drug discovery. https://lnkd.in/etW6eBS2 #AI #Biotech #DrugDiscovery #Proteomics #BaseFold #AIInHealthcare #Innovation #BioFocus #BasecampResearch

Google DeepMind's new AI is revolutionizing the field of protein design by creating proteins that can potentially cure diseases like cancer and COVID-19 in a fraction of the time it takes traditional methods. This AI model, called AlphaProteo, designs proteins that bind to specific targets, speeding up drug discovery and disease research. With its groundbreaking ability to outperform human-designed proteins, AlphaProteo is reshaping the future of medicine and biotechnology. #ai #google https://lnkd.in/ewKmWF9W

Discover how Life Edit Therapeutics is harnessing the power of Artificial Intelligence (AI) to advance protein discovery and engineering. Hear what Joel Parker and SHAORONG (Ron) CHONG, share what's happening inside the labs! Watch the full video below:

On the first day of CTA-Mas, let us introduce Turing Biosystems 🎄 Adam Amara and Rémy Boutonnet are incredible Cancer Tech Accelerator alumni and cofounded Turing Biosystems, an interpretable hybrid AI platform applies prior biological knowledge to patients and clinical data to select, optimize, and design therapies. Their technology is is capable of leveraging multiple layers of data such as multiomics data, microbiomes, diets, and clinical data to optimize therapies. Their venture have been named one of the 13 techbio startups to watch according to investors this year by Sifted. And excitingly, Turing Biosystems is opening up its reasoning and graph platform to allow clinical researchers across the world to compare the biology and associated clinical outcomes of patient cohorts in oncology and immune related diseases. 🧬 Check them out to learn more! https://turing.bio/ #AI #biosystems #holidays #founders #researchers #turingbio #awardwinning #cancertech

Love this latest story from Antonio Regalado in MIT Technology Review which captures the wild ride of AI in drug discovery -- from using AI to recognize cats in videos to designing highly optimized small molecule drugs in just a decade. It follows the journey of Insilico Medicine founder & CEO Alex Zhavoronkov whose mission to discover and design new treatments using AI has reached a key milestone -- Phase II trials with patients. It's an excellent read! Link in comments. #ai #genai #drugdiscovery #biotech

Profluent Secures $44M For AI-Driven Protein Design Learn more & get our take 👇 https://lnkd.in/gf5fDNtD “Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” – Ali Madani, Co-founder and CEO at Profluent “As they advance the frontier of AI research in the life sciences, Ali and Profluent are making biology programmable for the first time,” – Fraser Kelton, General Partner at Spark Capital “Historically, true disruption has occurred when two cutting-edge technologies intersect. Profluent is bridging AI and CRISPR,” – Hilary Eaton, PhD, Chief Business Officer at Profluent #CRISPR #ProteinDesign #SoHCNews